Nexalin Technology Reports Positive Alzheimer’s Trial Results

NEXALIN TECHNOLOGY shares are trading higher after the company announced significant improvements in cognitive performance and brain connectivity in Alzheimer's patients using its Gen-2 SYNC Neurostimulation Device.